Research work · 2020
Genomics of hypertension: the road to precision medicine
Nature Reviews Cardiology
Abstract
The known genetic architecture of blood pressure now comprises >30 genes, with rare variants resulting in monogenic forms of hypertension or hypotension and >1,477 common single-nucleotide polymorphisms (SNPs) being associated with the blood pressure phenotype. Monogenic blood pressure syndromes predominantly involve the renin–angiotensin–aldosterone system and the adrenal glucocorticoid pathway, with a smaller fraction caused by neuroendocrine tumours of the sympathetic and parasympathetic nervous systems. The SNPs identified in genome-wide association studies (GWAS) as being associated with the blood pressure phenotype explain only approximately 27% of the 30–50% estimated heritability of blood pressure, and the effect of each SNP on the blood pressure phenotype is small. A paucity of SNPs from GWAS are mapped to known genes causing monogenic blood pressure syndromes. For example, a GWAS signal mapped to the gene encoding uromodulin has been shown to affect blood pressure by influencing sodium homeostasis, and the effects of another GWAS signal were mediated by endothelin. However, the majority of blood pressure-associated SNPs show pleiotropic associations. Unravelling these associations can potentially help us to understand the underlying biological pathways. In this Review, we appraise the current knowledge of blood pressure genomics, explore the causal pathways for hypertension identified in Mendelian randomization studies and highlight the opportunities for drug repurposing and pharmacogenomics for the treatment of hypertension. In this Review, Padmanabhan and Dominiczak discuss how genomics has transformed our understanding of blood pressure regulation and hypertension, summarizing the current knowledge of blood pressure genomics and highlighting the opportunities and challenges for drug repurposing and pharmacogenomics for the treatment of hypertension. The genetic architecture of blood pressure encompasses approximately 30 genes, with rare variants involved in blood pressure dysregulation and >1,477 common single-nucleotide polymorphisms (SNPs) associated with blood pressure. Monogenic forms of blood pressure disorders involve both germline and somatic variants, with the latter predominantly seen in patients with neoplasms associated with hypertension. Most of the SNPs identified in genome-wide association studies (GWAS) as being associated with blood pressure are pleiotropic and mapped to non-coding regions of the genome, which makes functional mapping challenging. Although translating GWAS signals into causal mechanisms and clinical applications has been slow, Mendelian randomization studies are substantially improving our understanding of known epidemiological correlations between blood pressure and other traits. Pharmacogenomic studies of drug–gene interactions might offer a route to the early clinical translation of GWAS signals, with two clinical trials involving blood pressure GWAS SNPs currently ongoing. The genetic architecture of blood pressure encompasses approximately 30 genes, with rare variants involved in blood pressure dysregulation and >1,477 common single-nucleotide polymorphisms (SNPs) associated with blood pressure. Monogenic forms of blood pressure disorders involve both germline and somatic variants, with the latter predominantly seen in patients with neoplasms associated with hypertension. Most of the SNPs identified in genome-wide association studies (GWAS) as being associated with blood pressure are pleiotropic and mapped to non-coding regions of the genome, which makes functional mapping challenging. Although translating GWAS signals into causal mechanisms and clinical applications has been slow, Mendelian randomization studies are substantially improving our understanding of known epidemiological correlations between blood pressure and other traits. Pharmacogenomic studies of drug–gene interactions might offer a route to the early clinical translation of GWAS signals, with two clinical trials involving blood pressure GWAS SNPs currently ongoing.